Homology Medicines Inc. (NASDAQ: FIXX) stock closed at 2.03 per share at the end of the most recent trading day (a -9.78% change compared to the prior day closing price) with a volume of 4.37M shares and market capitalization of 116.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 206 people. Homology Medicines Inc. CEO is Arthur O. Tzianabos.

The one-year performance of Homology Medicines Inc. stock is -69.22%, while year-to-date (YTD) performance is -44.23%. FIXX stock has a five-year performance of %. Its 52-week range is between 1.3 and 8.9, which gives FIXX stock a 52-week price range ratio of 9.61%

Homology Medicines Inc. currently has a PE ratio of -22.40, a price-to-book (PB) ratio of 0.39, a price-to-sale (PS) ratio of 18.79, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -0.95%, a ROC of -1.09% and a ROE of -1.11%. The company’s profit margin is -47.29%, its EBITDA margin is -2 301.30%, and its revenue ttm is $5.47 Million , which makes it $0.10 revenue per share.

Of the last four earnings reports from Homology Medicines Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Homology Medicines Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Homology Medicines Inc. is Moderate Buy (2), with a target price of $13.83, which is +581.28% compared to the current price. The earnings rating for Homology Medicines Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Homology Medicines Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Homology Medicines Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.27, ATR14 : 0.22, CCI20 : 84.89, Chaikin Money Flow : -0.30, MACD : 0.07, Money Flow Index : 37.37, ROC : -8.56, RSI : 54.55, STOCH (14,3) : 48.65, STOCH RSI : 0.44, UO : 51.93, Williams %R : -51.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Homology Medicines Inc. in the last 12-months were: Albert Seymour (Option Excercise at a value of $0), Albert Seymour (Sold 1 661 shares of value $6 279 ), Arthur O. Tzianabos (Option Excercise at a value of $0), Arthur O. Tzianabos (Sold 5 354 shares of value $20 239 ), Gabriel Cohn (Option Excercise at a value of $0), Gabriel Cohn (Sold 1 661 shares of value $6 279 ), Timothy P. Kelly (Option Excercise at a value of $0), Timothy P. Kelly (Sold 2 974 shares of value $11 877 ), W. Bradford Smith (Option Excercise at a value of $0), W. Bradford Smith (Sold 2 182 shares of value $8 248 )